Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma

Drug Metabolism and Disposition

Volumn 43, Issue 1, 2015, Pages 140-146

  Gynther, Mikko ^a   Kariinen, Tiina M ^a   Hakkarainen, Jenni J ^c   Jalkanen, Aaro J ^c   Petsalo, Aleksanteri ^c   Lehtonen, Marko ^a   Peura, Lauri ^a   Kurkipuro, Jere ^a   Samaranayake, Haritha ^a,b   Yla Herttuala, Seppo ^a   Rautio, Jarkko ^a   Forsberg, Markus M ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b Aurealis Pharma Ltd   (Finland)

^c Aurealis Pharma Ltd ^*

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; BRAIN PERFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DIFFUSION; DRUG DISPOSITION; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; EXTRACELLULAR FLUID; GLIOMA; NONHUMAN; RAT; SINGLE DRUG DOSE; TUMOR VASCULARIZATION; ANIMAL; BRAIN TUMOR; MALE; METABOLISM; TUMOR CELL CULTURE;

RATTUS; SIMPLEXVIRUS;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; GANCICLOVIR; GLIOMA; MALE; RATS; TUMOR CELLS, CULTURED;

EID: 84919699174     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.059840     Document Type: Article

References (28)

1. Adachi M, Sampath J, Lan LB, Sun D, Hargrove P, Flatley R, Tatum A, Edwards MZ, Wezeman M, and Matherly L, et al. (2002) Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J Biol Chem 277:38998-39004.
2. Blakeley JO, Olson J, Grossman SA, He X, Weingart J, and Supko JG; New Approaches to BrainTumor Therapy (NABTT) Consortium (2009) Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J Neurooncol 91:51-58.
3. Bouw MR and Hammarlund-Udenaes M (1998) Methodological aspects of the use of a calibratorin in vivo microdialysis-further development of the retrodialysis method.Pharm Res 15:1673-1679.
4. Candolfi M, Curtin JF, Xiong WD, Kroeger KM, Liu C, Rentsendorj A, Agadjanian H, Medina-Kauwe L, Palmer D, and Ng P, et al. (2006) Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol Ther 14:371-381.
5. de Lange EC, de Vries JD, Zurcher C, Danhof M, de Boer AG, and Breimer DD (1995) The use of intracerebral microdialysis for the determination of pharmacokinetic profiles of anticancer drugs in tumor-bearing rat brain. Pharm Res 12:1924-1931.
6. El Hafny B, Chappey O, Piciotti M, Debray M, Boval B, and Roux F (1997) Modulation of P-glycoprotein activity by glial factors and retinoic acid in an immortalized rat brain microvessel endothelial cell line. Neurosci Lett 236:107-111.
7. Fletcher C, Sawchuk R, Chinnock B, de Miranda P, and Balfour HH, Jr (1986) Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 40:281-286.
8. Gynther M, Laine K, Ropponen J, Leppaampdie;nen J, Mannila A, Nevalainen T, Savolainen J, Jaampdie;rvinen T, and Rautio J (2008) Large neutral amino acid transporter enables brain drug delivery via prodrugs. J Med Chem 51:932-936.
9. Hu W and Liu W (2010) Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population. In Vitro Cell Dev Biol Anim 46:497-501.
10. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, and Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610-622.
11. Kalvass JC and Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: Implications for rational drug discovery. Biopharm Drug Dispos 23:327-338.
12. Kanu OO, Mehta A, Di C, Lin N, Bortoff K, Bigner DD, Yan H, and Adamson DC (2009)Glioblastoma multiforme: A review of therapeutic targets. Expert Opin Ther Targets 13:701-718.
13. Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, and vanTellingen O (2003) Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin Cancer Res 9 : 2849 - 2855.
14. Killian DM and Chikhale PJ (2001) A bioreversible prodrug approach designed to shift mechanism of brain uptake for amino-acid-containing anticancer agents. J Neurochem 76:966-974.
15. Laerum OD, Rajewsky MF, Schachner M, Stavrou D, Haglid KG, and Haugen A (1977) Phenotypic properties of neoplastic cell lines developed from fetal rat brain cells in culture after exposure to ethylnitrosourea in vivo. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 89:273-295.
16. Liu X, Tu M, Kelly RS, Chen C, and Smith BJ (2004) Development of a computational approach to predict blood-brain barrier permeability. Drug Metab Dispos 32:132-139.
17. .Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW,and Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system.Acta Neuropathol 114:97-109.
18. Pulkkanen KJ and Ylaampdie;-Herttuala S (2005) Gene therapy for malignant glioma: current clinical status. Mol Ther 12:585-598.
19. Reardon JE (1989) Herpes simplex virus type 1 and human DNA polymerase interactions with 29-deoxyguanosine 59-triphosphate analogues. Kinetics of incorporation into DNA and induction of inhibition. J Biol Chem 264:19039-19044.
20. Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, and Aboagye EO (2009) A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res 69:120-127.
21. Sandmair AM, Turunen M, Tyynelaampdie K, Loimas S, Vainio P, Vanninen R, Vapalahti M, Bjerkvig R,Jaampdienne J, and Ylaampdie-Herttuala S (2000) Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive gliomacells on treatment effect, survival time, and tissue reactions. Cancer Gene Ther 7:413-421.
22. Soininen SK, Lehtolainen-Dalkilic P, Karppinen T, Puustinen T, Dragneva G, Kaikkonen MU,Jauhiainen M, Allart B, Selwood DL, and Wirth T, et al. (2012) Targeted delivery via avidin fusion protein: intracellular fate of biotinylated doxorubicin derivative and cellular uptake kinetics and biodistribution of biotinylated liposomes. Eur J Pharm Sci 47:848-856.
23. Tian Q, Zhang J, Tan TM, Chan E, Duan W, Chan SY, Boelsterli UA, Ho PC, Yang H, and Bian JS, et al. (2005) Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm Res 22:1837-1853.
24. Tobias A, Ahmed A, Moon KS, and Lesniak MS (2013) The art of gene therapy for glioma:a review of the challenging road to the bedside. J Neurol Neurosurg Psychiatry 84:213-222.
25. Tyynelaampdie; K, Sandmair AM, Turunen M, Vanninen R, Vainio P, Kauppinen R, Johansson R,Vapalahti M, and Ylaampdie;-Herttuala S (2002) Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model. Cancer Gene Ther 9:917-924.
26. Wallstab A, Koester M, Böhme M, and Keppler D (1999) Selective inhibition of MDR1P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918. Br J Cancer79:1053-1060.
27. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, and Haefeli WE (2007) Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and nonnucleoside reverse transcriptase inhibitors. Drug Metab Dispos 35:340-344.
28. Westphal M, Ylä-Herttuala S, Martin J, Warnke P, Menei P, Eckland D, Kinley J, Kay R,and Ram Z; ASPECT Study Group (2013) Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma(ASPECT): A randomised, open-label, phase 3 trial. Lancet Oncol 14:823-833.